Cargando…
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147087/ https://www.ncbi.nlm.nih.gov/pubmed/32292577 http://dx.doi.org/10.18632/oncotarget.27407 |
| _version_ | 1783520348587687936 |
|---|---|
| author | Kim, Sunkyu Tiedt, Ralph Loo, Alice Horn, Thomas Delach, Scott Kovats, Steven Haas, Kristy Engstler, Barbara Schacher Cao, Alexander Pinzon-Ortiz, Maria Mulford, Iain Acker, Michael G. Chopra, Rajiv Brain, Christopher Tomaso, Emmanuelle di Sellers, William R. Caponigro, Giordano |
| author_facet | Kim, Sunkyu Tiedt, Ralph Loo, Alice Horn, Thomas Delach, Scott Kovats, Steven Haas, Kristy Engstler, Barbara Schacher Cao, Alexander Pinzon-Ortiz, Maria Mulford, Iain Acker, Michael G. Chopra, Rajiv Brain, Christopher Tomaso, Emmanuelle di Sellers, William R. Caponigro, Giordano |
| author_sort | Kim, Sunkyu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7147087 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71470872020-04-14 Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models Kim, Sunkyu Tiedt, Ralph Loo, Alice Horn, Thomas Delach, Scott Kovats, Steven Haas, Kristy Engstler, Barbara Schacher Cao, Alexander Pinzon-Ortiz, Maria Mulford, Iain Acker, Michael G. Chopra, Rajiv Brain, Christopher Tomaso, Emmanuelle di Sellers, William R. Caponigro, Giordano Oncotarget Correction Impact Journals LLC 2020-04-07 /pmc/articles/PMC7147087/ /pubmed/32292577 http://dx.doi.org/10.18632/oncotarget.27407 Text en Copyright: © 2019 Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Kim, Sunkyu Tiedt, Ralph Loo, Alice Horn, Thomas Delach, Scott Kovats, Steven Haas, Kristy Engstler, Barbara Schacher Cao, Alexander Pinzon-Ortiz, Maria Mulford, Iain Acker, Michael G. Chopra, Rajiv Brain, Christopher Tomaso, Emmanuelle di Sellers, William R. Caponigro, Giordano Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title_full | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title_fullStr | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title_full_unstemmed | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title_short | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
| title_sort | correction: the potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (lee011) is a versatile combination partner in preclinical cancer models |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147087/ https://www.ncbi.nlm.nih.gov/pubmed/32292577 http://dx.doi.org/10.18632/oncotarget.27407 |
| work_keys_str_mv | AT kimsunkyu correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT tiedtralph correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT looalice correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT hornthomas correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT delachscott correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT kovatssteven correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT haaskristy correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT engstlerbarbaraschacher correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT caoalexander correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT pinzonortizmaria correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT mulfordiain correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT ackermichaelg correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT choprarajiv correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT brainchristopher correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT tomasoemmanuelledi correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT sellerswilliamr correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels AT caponigrogiordano correctionthepotentandselectivecyclindependentkinases4and6inhibitorribocicliblee011isaversatilecombinationpartnerinpreclinicalcancermodels |